BP11141 PLGA 65:35, Hydroxyl Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa

PLGA 65:35, Hydroxyl Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa Description

PLGA 65:35, Hydroxyl Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa is produced from lactic and glycolic acid monomers at a 65:35 ratio. The hydroxyl termination provides reactive sites for further chemical modification, while the specified intrinsic viscosity and molecular weight influence degradation kinetics and mechanical properties. These technical attributes facilitate predictable performance in biomedical device fabrication and research applications.

PLGA 65:35, Hydroxyl Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa Applications

Healthcare and Biomedical Engineering
   - Use as a matrix in implantable drug delivery systems to achieve controlled release by leveraging its predictable degradation profile.
   - Applied as a scaffold in tissue engineering constructs to promote cell attachment by leveraging its bioresorbable properties.

Research and Development
   - Serves as a model polymer in degradation studies to evaluate biocompatibility by leveraging its defined molecular weight profile.
   - Used as a component in polymer blend experiments to assess processing behaviour by leveraging its intrinsic viscosity characteristics.

PLGA 65:35, Hydroxyl Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa Packing

The polymer is packaged in moisture-resistant, airtight containers constructed from inert plastic. Desiccants are included to mitigate moisture uptake, and each package is labelled with batch and product details. Storage in a cool, dry place is recommended. Custom packaging options accommodate varying quantities while maintaining product stability and integrity during storage and transportation.

Additional Information

PLGA polymers are widely studied in biomedical research due to their biodegradable properties and tunable degradation rates. The ratio of lactic to glycolic acid determines both the mechanical properties and degradation kinetics, providing a framework for predictable in vivo performance. Researchers extensively employ analytical techniques like NMR and gel permeation chromatography for batch verification.

Hydroxyl termination facilitates further chemical reactions, enabling conjugation with drugs, proteins, or other bioactive molecules. This functionalisation is pivotal in developing tailored drug delivery systems and tissue engineering scaffolds, ensuring that material modification aligns with specific application requirements.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.